PAIN
Volume 146, Issue 3 , Pages 253-260 , 5 December 2009

Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial

  • Amy S. Chappell

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 317 277 3846; fax: +1 317 276 6026.
    • ,
  • Melissa J. Ossanna

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN, USA
    • ,
  • Hong Liu-Seifert

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN, USA
    • ,
  • Smriti Iyengar

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN, USA
    • ,
  • Vladimir Skljarevski

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN, USA
    • ,
  • Linda Chunhong Li

      Affiliations

    • i3 Statprobe, Ann Arbor, MI, USA
    • ,
  • Robert M. Bennett

      Affiliations

    • Oregon Health & Science University, Portland, OR, USA
    • ,
  • Harry Collins

      Affiliations

    • Anderson & Collins Clinical Research, Inc., Edison, NJ, USA

Received 11 June 2008 ,Revised 1 June 2009 ,Accepted 18 June 2009.

References 

  1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039–1049
  2. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984
  3. Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15
  4. Ash G, Dickens CM, Creed FH, Jayson MI, Tomenson B. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology (Oxford). 1999;38:959–967
  5. Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain. 2001;93:107–114
  6. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897
  7. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol. 1979;47:343–352
  8. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840
  9. Bradley LA, Kersh BC, DeBerry JJ, Deutsch G, Alarcon GA, McLain DA. Lessons from fibromyalgia: abnormal pain sensitivity in knee osteoarthritis. Novartis Found Symp. 2004;260:258–270
  10. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43–53
  11. Clauw DJ, Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum. 2009;60:321–324
  12. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138
  13. Department of Health and Human Services, Food and Drug Administration [Docket No. 97D-0174]. In: International conference on harmonisation: guidance on statistical principles for clinical trials. Federal Register, vol. 63, no. 179, Wednesday, September 16, 1998. Notices: 49583–98.
  14. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158
  15. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: The disease and its risk factors. Ann Intern Med. 2000;133:635–646
  16. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219–245
  17. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007;23:175–184
  18. Goldstein DJ, Lu Y, Detke MJ, Hudson JI, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45:17–28
  19. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118
  20. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health; 1976. p. 76–338.
  21. Hartford JT, Endicott J, Kornstein SG, Allgulander C, Wohlreich MM, Russell JM, et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim care companion. J Clin Psychiatry. 2008;10:197–204
  22. Imamura M, Imamura ST, Kaziyama HH, Targino RA, Hsing WT, de Souza LP, et al. Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: a controlled analysis. Arthritis Rheum. 2008;59:1424–1431
  23. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin–norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311:576–584
  24. Jan MH, Lin JJ, Liau JJ, Lin YF, Lin DH. Investigation of clinical effects of high- and low-resistance training for patients with knee osteoarthritis: a randomized controlled trial. Phys Ther. 2008;88:427–436
  25. Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain. 2002;100:55–64
  26. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther. 2005;312:726–732
  27. Kidd BL. Osteoarthritis and joint pain. Pain. 2006;123:6–9
  28. Kind P. The EuroQoL instrument: an index of health-related quality of life. In:  Spilker B editors. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott–Raven Publishers; 1996;p. 191–201
  29. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–799
  30. Mangani I, Cesari M, Kritchevsky SB, Maraldi C, Carter CS, Atkinson HH, et al. Physical exercise and comorbidity. Results from the Fitness and Arthritis in Seniors Trial (FAST). Aging Clin Exp Res. 2006;18:374–380
  31. McAlindon TE, Cooper C, Kirwan JR, Dieppe PA. Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis. 1993;52:258–262
  32. Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med. 2007;8:397–409
  33. Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356
  34. Sullivan MD, Bentley S, Fan MY, Gardner G. A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain. J Pain. 2009;10:208–213
  35. van Meurs JB, Uitterlinden AG, Stolk L, Kerkhof HJ, Hofman A, Pols HA, et al. A functional polymorphism in the catechol-O-methyltransferase gene is associated with osteoarthritis-related pain. Arthritis Rheum. 2009;60:321–324
  36. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute New England Medical Center; 1993.
  37. Wernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–1420
  38. Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry. 2007;68:1921–1930
  39. Wodehouse T, Cruwys S, Kay R, Graven-Nielsen T, Arendt-Nielsen L, Langford R, Kidd BL. Osteoarthritis and its association with mechanical hyperalgesia: an experimental controlled study. In: Abstracts of the 12th world congress on pain, international association for the study of pain (IASP), Glasgow, Scotland, 17–22 August 2008 [CD-ROM]. No. PW 044. ISSN/ISBN: 978-0-931092-74-9.
  40. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137–162
  41. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370

PII: S0304-3959(09)00369-8

doi: 10.1016/j.pain.2009.06.024

PAIN
Volume 146, Issue 3 , Pages 253-260 , 5 December 2009

Article Tools

* Image Usage & Resolution